EDAP TMS S.A. (NASDAQ:EDAP) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research report issued on Tuesday.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

EDAP has been the topic of a number of other reports. ValuEngine raised EDAP TMS from a “sell” rating to a “hold” rating in a report on Friday, May 19th. HC Wainwright set a $7.00 price objective on EDAP TMS and gave the company a “buy” rating in a report on Wednesday, July 19th.

EDAP TMS (NASDAQ:EDAP) opened at 2.94 on Tuesday. The firm’s 50-day moving average is $2.99 and its 200-day moving average is $2.89. EDAP TMS has a 12-month low of $2.25 and a 12-month high of $3.85. The stock’s market capitalization is $85.25 million.

EDAP TMS (NASDAQ:EDAP) last announced its quarterly earnings data on Wednesday, August 23rd. The medical equipment provider reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by $0.03. The firm had revenue of $10.40 million during the quarter, compared to analyst estimates of $10 million. EDAP TMS had a negative net margin of 0.27% and a positive return on equity of 15.70%. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.10 earnings per share. Analysts predict that EDAP TMS will post $0.01 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “EDAP TMS S.A. (EDAP) Stock Rating Lowered by Zacks Investment Research” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/31/edap-tms-s-a-edap-stock-rating-lowered-by-zacks-investment-research.html.

Hedge funds have recently modified their holdings of the company. Virtu KCG Holdings LLC bought a new stake in shares of EDAP TMS during the second quarter worth approximately $117,000. Essex Investment Management Co. LLC bought a new stake in shares of EDAP TMS during the second quarter worth approximately $172,000. Hilton Capital Management LLC increased its stake in shares of EDAP TMS by 43.1% in the second quarter. Hilton Capital Management LLC now owns 83,000 shares of the medical equipment provider’s stock worth $274,000 after buying an additional 25,000 shares during the last quarter. Finally, Archon Capital Management LLC bought a new stake in shares of EDAP TMS during the second quarter worth approximately $2,474,000. Hedge funds and other institutional investors own 9.49% of the company’s stock.

EDAP TMS Company Profile

EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.

Receive News & Stock Ratings for EDAP TMS S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EDAP TMS S.A. and related stocks with our FREE daily email newsletter.